The vision of Kaiku Health is that every cancer patient should have access to personalised digital health intervention. To achieve this, Kaiku Health provides its Life Sciences partners with the possibility to co-create therapy-specific modules to engage patients throughout their treatment journey. The co-created modules track symptoms, notify care teams and provide personalised support for patients.
Kaiku Health’s multidisciplinary team consists of oncologists, User Experience designers, software developers, and data scientists. By combining our experience in developing software as a medical device with our Life Sciences partner’s expertise in cancer treatment development, we can co-create truly novel digital patient support programs to improve patients’ engagement and experience in their treatment.
Our pioneering technology, powered by Machine Learning, is developed in compliance with international standards and is compliant with applicable medical device legislation. This ensures that co-created modules of our partners are always fully compliant with the applicable regulatory requirements. For instance, Kaiku Health is classified as a Class IIa Medical Device in Europe and a Medical Device under FDA’s enforcement discretion in the United States.
In collaboration with cancer research institutes, clinics and life sciences partners, we strive for being the forerunner in digital management of the most novel cancer therapies.
In addition to implementing the co-created module at cancer centers, Kaiku Health ensures that clinics are also capable of supporting other patients of their institute – regardless of the therapies they are receiving.
Kaiku Health works jointly with its Life Sciences partners to better identify the treatment journey of each individual patient. By offering this tailored approach, the co-created modules can act as digital patient support programs to improve patient experience, timeliness, and accuracy of interventions of the healthcare providers. This also ensures that doctors and nurses can spend more time during clinic visits on the topics that are most important for the patient and her treatment.
Similarly as physical drugs, also digital solutions have the potential to improve clinical outcomes of patients. By joining forces with Kaiku, the Life Sciences partner embarks on a journey to start supporting their patients beyond traditional medicine. Many countries, including Germany, Belgium, and France, are already granting reimbursement to digital solutions supporting patients’ treatments.
Granting clinics access to a therapy-specific module in routine care enables the Life Sciences partner to get anonymised and aggregated RWD on the symptoms of their medicine, from real-world use cases. Combined with the possibility to utilise Kaiku’s therapy-agnostic modules alongside the co-created module enables a rich pool of RWD for potential Phase 4 study settings.
Our digital platform is developed in continuous collaboration with patients, healthcare professionals, and researchers. By bringing together experts from all fields and sharing knowledge we can take clinical outcomes and efficiency to the next level.
This whitepaper discusses the adoption of digital services by cancer patients which has been found to increase health-related quality of life and several aspects of patient experience. It presents several hindrances and facilitators of patient adoption and offers concrete steps to promote the use of digital health services by cancer patients. Read the full paper to learn more.
In collaboration with Oulu University Hospital (OYS), Kaiku Health conducted a study which investigated whether machine learning (ML) could be used to predict the treatment response, or more specifically objective response rate (ORR) of ICI treated patients, based on clinical and patient-reported data. ORR was defined as the proportion of patients in whom partial (PR) or complete (CR) responses were seen as the best overall response.
Kaiku Health and Oulu University Hospital (OYS) aim to increase the understanding behind treatment benefit and onset of complex immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapies. The findings from this study conducted were currently presented in the prestigious ESMO 2020 Virtual Congress.
